Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) is a clinical-stage biopharmaceutical company focused on inflammatory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). Its news flow centers on the development of its lead antibody candidate, rademikibart, and on corporate and regulatory milestones that shape the company’s trajectory.
Readers following CNTB news can expect regular updates on clinical progress, including recruitment status and topline data timing for the Phase 2 Seabreeze STAT asthma and Seabreeze STAT COPD studies, which evaluate rademikibart as an adjunct treatment for acute exacerbations. Company announcements also highlight new mechanism of action findings, post-hoc analyses of Phase 2b asthma data, and presentations at major medical meetings such as the European Respiratory Society Congress, the American Thoracic Society International Conference, and the European Academy of Allergy and Clinical Immunology Congress.
News items frequently cover regulatory and partnership developments, including the exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd. in Greater China and the submission and acceptance of a New Drug Application for rademikibart for atopic dermatitis by China’s National Medical Products Administration. Investors also see coverage of capital markets actions, such as the termination of the company’s American Depositary Receipt program and the direct listing of its ordinary shares on the Nasdaq Global Market under the symbol CNTB.
Additional CNTB news includes financial results, board appointments, and community initiatives, such as the collaboration with the Jovante Woods Foundation to expand asthma education programs. For investors, analysts, and healthcare observers, this news page provides a centralized view of Connect Biopharma’s clinical, regulatory, financial, and outreach activities related to rademikibart and its broader inflammatory disease focus.
Connect Biopharma has reported significant results from its Phase 2b clinical trial for CBP-201, a treatment for moderate-to-severe atopic dermatitis. The trial achieved both primary and key secondary endpoints, showing substantial improvements in skin clearance, disease severity, and itch compared to placebo. Patients with higher baseline disease severity experienced greater efficacy, indicating a competitive safety profile. CBP-201 features a differentiated Q4W dosing schedule, enhancing its appeal in the market.
Connect Biopharma (Nasdaq: CNTB) reported positive results from its Phase 2b trial of CBP-201 for moderate-to-severe atopic dermatitis, demonstrating significant improvements in skin clearance and a favorable safety profile compared to placebo. The trial met all primary and key secondary endpoints, showing strong efficacy for both Q2W and Q4W dosing regimens. A Phase 3 trial is set to begin in the second half of 2022. Further analysis indicated that patients with higher baseline disease severity experienced greater treatment benefits. Key safety metrics revealed low incidence of adverse events.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will host a conference call and webcast on January 5, 2022, at 8:30 AM Eastern Time to discuss detailed data from its Phase 2b trial of CBP-201 for moderate-to-severe atopic dermatitis. The trial aims to evaluate the safety and efficacy of CBP-201, an antibody targeting IL-4Rα. This call is a significant step for Connect Biopharma as they continue to advance their pipeline of therapies for chronic inflammatory diseases. Interested parties can access the call via a provided link or by phone.
Amberstone Biosciences has successfully completed a $12 million Series A financing round, led by Viva BioInnovator, Co-win Ventures, and Sinovation Ventures, among others. The funds will be utilized to advance their tumor microenvironment activated therapeutic programs to the investigational new drug application (IND) enabling stage. CEO George Wu expressed gratitude for investor support, emphasizing their goal of developing safer and more effective therapies for cancer patients.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) has appointed Mr. Steven Chan as Chief Financial Officer, effective November 22, 2021. Chan brings over 25 years of financial expertise from various sectors, including healthcare and biotechnology. He succeeds Eric Hall, who served as Interim CFO. Chan's experience includes leadership roles in notable companies like Arcus Biosciences and Myokardia. He expressed enthusiasm for leading the finance function at Connect, highlighting potential for growth following the company's recent IPO and progress in its innovative pipeline.
Connect Biopharma (Nasdaq: CNTB) has officially completed enrollment in its Phase 2 clinical trial for CBP-307, a treatment for moderate-to-severe ulcerative colitis, involving 134 patients. This trial, which takes place over 12 weeks, includes an induction phase followed by a maintenance phase for responders. CEO Zheng Wei expressed optimism about CBP-307's potential to fill an unmet need in UC therapies. Topline results are expected by the end of Q1 2022, building on promising Phase 1 findings showcasing its safety and T cell modulation effects.
Connect Biopharma reported positive topline results from its global Phase 2 trial of CBP-201 for adult patients with moderate-to-severe atopic dermatitis. The trial met its primary endpoint, showing statistically significant Eczema Area and Severity Index (EASI) score reductions across all treatment arms compared to placebo. Key secondary endpoints also demonstrated efficacy. CBP-201 exhibited a favorable safety profile with low incidence of adverse events. The Company plans to initiate a Phase 3 trial program in mid-2022 to further explore the therapeutic potential of CBP-201.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that CEO Dr. Zheng Wei and Chief Business Officer Dr. Selwyn Ho will participate in fireside chats at two healthcare conferences.
- Jefferies London Healthcare Conference: Available on-demand from November 18 at 8:00 a.m. GMT.
- 33rd Annual Piper Sandler Healthcare Conference: Available on-demand from November 22 at 10:00 a.m. ET.
Webcasts will be accessible on the Company’s Investor Relations page. Connect Biopharma focuses on therapies for chronic inflammatory diseases, with product candidates targeting conditions like atopic dermatitis and ulcerative colitis.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that Dr. Zheng Wei, CEO, and Dr. Selwyn Ho, Chief Business Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on October 26, 2021, at 1:00 PM ET. A webcast of the discussion will be available on the Company's Investor Relations page, with a replay accessible afterward. Connect Biopharma focuses on developing therapies for chronic inflammatory diseases, with lead candidates CBP-201 and CBP-307 currently in clinical trials for conditions like atopic dermatitis and ulcerative colitis.
Connect Biopharma (Nasdaq: CNTB) announced the dosing of the first subject in a Phase 2 trial for CBP-201, targeting chronic rhinosinusitis with nasal polyps (CRSwNP). This randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy of CBP-201 in reducing nasal polyp scores and congestion in patients inadequately controlled by current therapies. The study enrolls approximately 140 subjects across 60 sites globally. CBP-201 targets interleukin-4 receptor alpha and has shown promise in earlier trials for various inflammatory diseases.